Home » Uncategorized » Novartis and Immunogen Sign Deal to Develop Novel Cancer Treatments

Switzerland’s Novartis AG and Immunogen Inc. have signed a collaboration deal to develop novel cancer treatments. Immunogen will receive an upfront fee of $45 million.

Under the arrangement, Novartis and Immunogen will work together to develop so-called antibody drug conjugates to treat cancer, a novel technology that is considered to be more effective than traditional chemotherapy.

Unlike in chemotherapy, where cancerous and healthy cells are destroyed during treatment, Immunogen’s technology includes cancer-killing agents that are attached to an antibody that can be directly transported to affected cells. This targeted therapy helps to reduce side-effects that are common in chemotherapy.

Outsmart cancer

  • "Cancer does not have to be a death sentence"

    Let’s Find Out How To Be Cancer Proof!